Join BenevolentAI’s VP Applied Sciences at One Nucleus Genesis where she will be speaking on 'Hope, Hype and Reality of AI in Drug Discovery’.
10 Minute Presentation: Introduction to what Pharma needs from AI with Vishal Sahni
10 Minute Presentation: Approaching AI in Drug Discovery with Alix Lacoste
Close: Q&A discussion on the potential and challenges of applying AI in drug discovery with:
Vishal Sahni | Director Discovery Research, MSD
Alix Lacoste | VP Applied Sciences, BenevolentAI
Steve Crossan | VP AI and ML at GSK
Alix has significant experience using data science and machine learning to advance biomedical discoveries. She holds a PhD in Molecular and Cellular Biology from Harvard University. Previously at IBM Watson Health, Alix led computational research projects in target identification and drug repurposing, most notably for Parkinson’s disease and amyotrophic lateral sclerosis, in collaboration with academic and pharma partners. At BenevolentAI, Alix connects AI and Drug Discovery groups to continuously improve the hypothesis generation pipeline.